170 related articles for article (PubMed ID: 16466670)
1. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients.
Lee BH; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):658-62. PubMed ID: 16466670
[TBL] [Abstract][Full Text] [Related]
2. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Holzer L; Eap CB
J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
[TBL] [Abstract][Full Text] [Related]
3. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
4. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
6. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia.
Yuan HN; Wang CY; Sze CW; Tong Y; Tan QR; Feng XJ; Liu RM; Zhang JZ; Zhang YB; Zhang ZJ
J Clin Psychopharmacol; 2008 Jun; 28(3):264-370. PubMed ID: 18480682
[TBL] [Abstract][Full Text] [Related]
7. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
[TBL] [Abstract][Full Text] [Related]
8. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Troost PW; Lahuis BE; Hermans MH; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
J Clin Psychopharmacol; 2007 Feb; 27(1):52-7. PubMed ID: 17224713
[TBL] [Abstract][Full Text] [Related]
9. Risperidone in the treatment of psychotic depression.
Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110
[TBL] [Abstract][Full Text] [Related]
10. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
[TBL] [Abstract][Full Text] [Related]
11. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders.
Eberhard J; Lindström E; Holstad M; Levander S
Acta Psychiatr Scand; 2007 Apr; 115(4):268-76. PubMed ID: 17355517
[TBL] [Abstract][Full Text] [Related]
12. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
13. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
Anderson GM; Scahill L; McCracken JT; McDougle CJ; Aman MG; Tierney E; Arnold LE; Martin A; Katsovich L; Posey DJ; Shah B; Vitiello B
Biol Psychiatry; 2007 Feb; 61(4):545-50. PubMed ID: 16730335
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
15. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
16. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Kopecek M; Bares M; Horacek J; Mohr P
Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Kissling W; Glue P; Medori R; Simpson S
Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
[TBL] [Abstract][Full Text] [Related]
18. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sato Y; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1230-4. PubMed ID: 17559997
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
